Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DF1001 first-in-human study in advanced solid tumors
NL-OMON52911Phase 2Recruiting
- Sponsor
- Dragonfly Therapeutics
- Start
- Sep 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of DF1001 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), transitional cell carcinoma (TCC) and 3 more (4 arms), sponsored by Dragonfly Therapeutics. Primary endpoints: Dose-limiting toxicities, Safety and tolerability and 4 more. Started Sep 2021; status: recruiting.
02
Drugs
DF1001
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)transitional cell carcinoma (TCC)breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NL-OMON52911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52911.